The announcement is based on a study involving 1,057 participants with COVID-19.
By the 29th day, 1 percent of participants who received the antibody were hospitalized for more than 24 hours, while 6 percent of participants in the placebo group were hospitalized for more than 24 hours. After examining the data, researchers said that it is possible that half of the patients who received sotrovimab and were hospitalized for more than 24 hours were there for reasons other than progression of COVID-19, while this was not the case for participants in the placebo group.
The National Institutes of Health has authorized sotrovimab for non-hospitalized people with mild-to-moderate COVID-19 who are at high risk of clinical progression.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
